Skip to content
MARKETS / NASDAQ / ZCMD
NASDAQ · SERVICES-EDUCATIONAL SERVICES · SMALL CAP

Zhongchao Inc. ZCMD

9 fiscal years on record · USD · FY2025 reported · SEC filings only
$11.4M
▼ 28.3% YoY
$-6.3M
In brief

What this company does

We conduct our business through the VIE, Zhongchao Medical Technology (Shanghai) Corp., or Zhongchao Shanghai, a PRC company, and through 7 subsidiaries of Zhongchao Shanghai, including Shanghai Zhongxun, Shanghai Zhongxin, Beijing Boya, Shanghai Huijing, Xinjiang Pharmaceutical, Beijing Zhongxuanboya, West Angel, and Shanghai Zhongxuan, each a PRC company. We are not a Chinese operating company, but an offshore holding company incorporated in the Cayman Islands. Zhongchao Shanghai, together with its subsidiaries, is a platform-based internet technology company offering services to patients with oncology and other major diseases in China. The Company ceased operations of Xinjiang Pharmaceutical on June 30, 2025. We intend to procure additional space as we add employees and expand geographically.

Written from the business description in Zhongchao Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 3 April 2026. Every sentence was checked against that document before publication.

Growth
USD 11.4M
Revenue, FY2025 · full 9-year series below
Revenue $M Net income $M
FY2025 · Revenue 11.4 · Net income -6.3
8M16M-4M-8M201720182019202020212022202320242025
Compound annual growth
−7.0%
−8.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −8.8% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−51 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -54.4% · Net -51.1%
10%20%-20%-40%-60%201720182019202020212022202320242025
ROE
FY2025 · ROE -32.0%
10%20%30%-20%-40%201720182019202020212022202320242025

Each USD of equity lost 32 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $
FY2019 · FCF 95079.0
250000.0500000.0-200000.0-400000.0201720182019202020212022202320242025

Total assetsUSD 24.1M
EquityUSD 18.6M
CashUSD 8.1M
Current ratio11.11×

Equity funds 77% of total assets.

The 9-year record
9 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017
Revenue $B0.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.00.00.00.00.0
EBITDA $B−0.0−0.0−0.0−0.00.00.00.00.00.0
Income tax $B0.00.0−0.00.0−0.00.00.00.0−0.0
Net income $B−0.0−0.0−0.0−0.00.00.00.00.00.0
Free cash flow $B······0.00.0−0.0
EPS, diluted $−1.85−0.99−34.83−1.130.100.180.190.140.08
Dividend / sh $·········
Payout %·········
ROE %−32.0−3.3−47.3−9.40.718.930.326.5·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 42 reconciliationsAUDITED

Reconciled in 9 of 19 fiscal years. 53 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Educational Services
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image